A study of EnGeneIC Dream Vectors (EDV’s) packaged with the chemotherapy, E-EDV-D682 given simultaneously as non-targeted EDVs carrying an immune enhancer called EDV-GC, in participants with advanced epidermal growth factor expressing cancers whose disease has progressed after one or two treatment regimes, or where other standard therapies are not appropriate. (EGFR EDV-D682/GC Trial)

ACTRN 12625000203459

Brief Summary

This study aims to determine whether E-EDV-D682 in combination with the adjuvant treatment, EDV-GC is safe and effective and to identify the most responsive cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs indications (advancedat a late stage, far along EGFR-expressing solid tumors) to the E-EDV-D682/GC treatment.

Intervention/Treatment

• Drug: E-EDV-D682/GC

Inclusion Criteria

• Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance score of 0-1.
• Life expectancy of greater than or equal to 3 months.
• Measurable disease per iRECIST criteria.
• Adequate haematological function.
• Adequate renal function as follows.
• Adequate hepatic function.
• Adequate cardiac function with LVEF of greater than or equal to 50% at baseline.
• The subject must have positive EGFR expression on local IHC or liquid biopsyremoval of a section of tissue to analyse for cancer cells.